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Introduction: Despite the controversy concerning sentinel lymph node biopsy (SLNB) in papillary thyroid
carcinoma (PTC), successful detection rates can be achieved by radioguidance and vital dyeing. However,
the drawbacks in both techniques are notable. Magnetic-guided SLNB (mSLNB) using superparamagnetic
iron oxide (SPIO) nanoparticles is appealing as an alternative procedure.
Materials and Methods: mSLNB using the Sentimag-Sienna System®, total thyroidectomy and central
compartment dissection (CCD) were performed on all PTC patients. Lymph node involvement was
assessed by postoperative pathological examination.
Results: From 2014 to 2016, 33 consecutive patients with PTC were enrolled in the study. A total of 20
patients met the eligibility. mSLNB succeeded in 16 patients, with a detection rate of 80%. A median of
two SLN per patient were detected. A median of 10.5 non-sentinel lymph nodes (NSLN) from CCD were
examined. Among the patients, 56.25% (9/16) had no metastatic nodes, while 12.5% (2/16) had exclu-
sively SLN involvement. No false negative cases were found. The agreement between SLN and NSLN
status was 87.5%. The prediction of NSLN involvement by SLN status showed 100% sensitivity, 81.8%
specificity, 71.4% PPV and 100% NPV. Subsequently, mSLNB and the final pathological analysis would
discriminate 43.75% (7/16) of patients who would certainly benefit from CCD whilst 56.25% of the total
would confirm an unnecessary lymphadenectomy and avoid morbidity.
Conclusion: mSLNB showed satisfactory performance in PTC with clinical-negative nodes. We have
shown mSLNB to be a good predictor of central compartment status that can improve the staging and
management of PTC patients.
© 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical
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Differentiated thyroid cancer (DTC) is the most common endo-
crine malignancy. Papillary carcinoma represents 60e70% among
all thyroid carcinomas. Surgical treatment of papillary thyroid
cancer (PTC) is carried out by total thyroidectomy and neck
dissection in patients with clinical involvement of nodes or cT3/cT4
[1,2]. Nevertheless, “prophylactic” central neck dissection in pa-
tients with clinically negative lymph nodes is still controversial [3].
In comparison with simple thyroidectomy, CCD causes higher
postsurgical adverse effects such as hypoparathyroidism oropean Society of Surgical Oncology. All rights reserved.
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tral compartment lymphadenectomy is performed [3e5].
The prevalence of nodal involvement associated with PTC is
significant, especially in high-risk patients (up to 75%) [6,7].
Moreover, nodal involvement affects the survival of patients older
than 45 or with other risk factors [8]. There is a clear association
between nodal involvement and loco-regional recurrence, as such
surgery is the optimal treatment [2]. However, morbidity after
surgery to review recurrence is also remarkable. Apart from other
consequences, permanent recurrent nerve paralysis and hypo-
parathyroidism are not uncommon, there might be a need for a
voluntary parathyroid gland and recurrent nerve resection due to
involvement, as well as compressive haematoma or temporary
tracheostomy while even cases of fatalities have been described
[9e13].
The sentinel lymph node (SLN) is defined as the first lymph
node receiving lymphatic drainage from a primary tumour, be-
ing the first node to be affected by metastasis. Hence, low or no
likelihood of distant lymphatic spread is assumed for histolog-
ically negative SLN. The concept of SLN is currently established
in melanoma, vulvar and breast cancer patients, and it is being
assessed in other types of solid tumours including differentiated
thyroid carcinoma [14e16]. In thyroid cancer, SLN biopsy (SLNB)
has been addressed using blue dyes [17,18], radioisotopes
[4,19e22] or the combination of both [23]. The pooled detection
rate of vital dyes is 15% lower than the rate for radioguided
SLNB [24]. The drawbacks of using radiotracers with lympho-
scintigraphy include radiation exposure and the need for nu-
clear medicine facilities, while allergic reactions have been
associated with blue dyeing [25]. In PTC, the SLNB contributes to
an accurate perioperative staging of the disease [6,9,10] and
could help in selecting patients who would certainly benefit
from CCD while avoiding unnecessary surgery and its associated
morbidity [2,6,26]. However, the current clinical guidelines for
PTC management do not consider the SLNB procedure due to
the high false negative ratio (FNR) in intraoperative SLN analysis
[27].
The Sentimag-Sienna System® is a new technology for SLNB
based on a magnetic tracer. Superparamagnetic iron oxide (SPIO)
has been used for over 20 years as an intravenous contrast agent for
magnetic resonance imaging (MRI) [28]. Due to the super-
paramagnetic conduct, the response of SPIO to an external mag-
netic field and its magnetic properties disappears if the magnetic
field is discontinued. The Siennaþ® SPIO tracer is covered by car-
boxidextran, which prevents agglomeration while preserving
biocompatibility. The particle size, with a median diameter of
60 nm including the organic cover, allows for the selective filtering
of Siennaþ® by lymph nodes (LN), lymphatic drainage and final
accumulation in the nodes. Hence, the SPIO in nodes can be
detected using the Sentimag® handheld magnetometer. The feasi-
bility of SPIO and the Sentimag-Sienna System® has been already
proven for SLNB in breast cancer with detection rates equal to the
referencemethodology such as radiotracer or radiotracer combined
with blue dye [29e34].
The aim of this study was to evaluate the Sentimag-Sienna
System® for SLNB in PTC patients with PTC and clinically negative
nodes. The performance of magnetic-guided SLNB to predict node
involvement in the central compartment was also investigated.
MATERIALS and METHODS
Study design
This is prospective single-institution study. Consecutive patients
with thyroid cancer from 2013 to 2016 were considered for thePlease cite this article as: Baena Fustegueras JA et al., Magnetic detection o
study results, European Journal of Surgical Oncology, https://doi.org/10.1study. The inclusion criteria were pathological confirmation of
papillary thyroid carcinoma, clinical-negative lymph nodes in the
central compartment and non-lateral compartment involvement,
as well as no previous surgical treatment in the cervical area. Pa-
tients were excluded if any contraindication to magnetic tracer
such as intolerance to iron or dextran compounds, high iron con-
centration disorders or metallic implants existed. The study was
approved by the Ethics Committee of the Arnau de Vilanova Uni-
versity Hospital in Lleida, Spain (reference MAGIC-PAT). Only
eligible patients who provided the signed informed consent were
enrolled in the study.
SLNB procedure with magnetic tracer
All patients were subjected to a total thyroidectomywith central
compartment dissection through a standard Kocher incision. After
the thyroid gland dissection, the SPIO magnetic tracer Siennaþ®
(Endomagnetics Ltd, UK) was peritumoral injected, following the
manufacturer's instructions. A 5-min massage was performed to
trigger the tracer's migration into the LN. The handheld Sentimag®
magnetometer (Endomagnetics Ltd, UK) was used to detect the
magnetic field 20min post-injection, and the magnetic count was
checked at the injection point and central compartment region.
Subsequently, a total thyroidectomy was performed and the mag-
netic count in the central compartment was tested. The dissection
of SLN was stopped if the node count was less than 5% of the
maximum count. Finally, central compartment dissection was
performed. No metal surgical instruments or armoured endotra-
cheal tubes were used in the surgical procedure to prevent inter-
ference. All mSLNB procedures were performed by the same
surgeon (JAB). The sentinel compartments were referred to post-
operative pathological examination.
Pathological assessment
As the limited operative area in the central compartment made
occasionally difficult to dissect individual SLN in vivo, the presence
and number of LNs in the tissue excised, we called sentinel
compartment (SC), was assessed in the post-operative pathological
study. The status of SLN and non-sentinel lymph nodes (NSLN) from
the central compartment dissectionwas assessed following current
pathology laboratory practice (AJCC 7th Ed.) [6,35].
Statistical analyses
The descriptive analysis of the variables was carried out by
dispersion and central tendency parameters. Quantitative variables
were described using means and standard deviations. Per node
analysis was conducted for the global pathological LN results. Per
patient data analysis was performed for mSLNB procedure and
prediction of CC status. With regards to the central compartment
status prediction, true SLN was assumed if either positive SLN or
the negative status of both SLN and NSLN was observed. Negative
SLN but positive NSLN was considered a false negative case. The
FNR of SLNB as a predictor of the central compartment status was
defined as the proportion of false negative cases over histologically
positive NSLN cases.
Results
SLNB procedure with magnetic tracer
A total of 31 patients with a diagnosis of PTC were enrolled in
the study. Eleven cases were excluded due to not complying with
the eligibility criteria. Among them, 7 cases were excluded due tof sentinel lymph node in papillary thyroid carcinoma: TheMAGIC-PAT
016/j.ejso.2019.03.017
Table 1
Clinic and pathological characteristics of PTC patients.
Patients (n¼ 20) N (%)
Agea 56 (22e78)
Gender
Male 5 (25.0%)
Female 15 (75.0%)
Clinical diagnose
Palpation 7 (35.0%)
Ultrasound 11 (55.0%)
Others 2 (10.0%)
Tumour location
Right lobe 8 (40%)
Left lobe 9 (45%)
Isthmus 3 (5%)
Multifocality
No 15 (75.0%)
Yes 5 (25.0%)
Tumour size (max in image)a 16.5 (8.0e53.0)
Clinical T stage
T1 10 (50%)
J.A. Baena Fustegueras et al. / European Journal of Surgical Oncology xxx (xxxx) xxx 3perioperative N1 stage (lateral compartment dissection proceed), 2
misplaced tumour nodes, 1 incompatibility with the surgical pro-
cedure and magnetic tracer (metal instruments), and 1 case due to
missing data (Fig. 1).
Therefore, 20 patients met the eligibility criteria to evaluate the
performance of SLNB. The clinical-pathological characteristics of
these patients are depicted in Table 1. Out of the total, 75% of pa-
tients were women. The average age was 54.8 years. A single
tumour node was found in 75% cases. The patients had clinical T1
(50%) and T2 (50%) tumours. Final pathological examination evi-
denced 60% (12/20) cases with pT3 tumours. The pathological ex-
amination of LN after CCD evidenced 45.0% (9/20) patients with
nodal involvement (pN1).
The sentinel compartment was excised in 17 cases (Table 2). In
82.4% (14/17) of patients, a single area was detected. In 3 (17.6%)
cases, two different areas were excised. Among the 20 patients, 16
had successful SLNB while 4 cases failed to detect SLN. Three fail-
ures occurred due to the non-migration of magnetic tracer and 1
case failed since non-lymphatic tissue was detected in the patho-
logical assessment. The SLNB detection rate using the magnetic
tracer was 80% (16/20).T2 10 (50%)
pT stage
T1 3 (15.0%)
T2 5 (25.0%)
T3 12 (60.0%)
pN stage
N0 11 (55.0%)
N1 9 (45.0%)
a Data as median and range.Lymph node involvement
A median of 12 (3e23) LN per patient were assessed (Table 3).
The ratio of metastatic nodes was 14.0% (32/229), with a median of
0 (0e10) positive LN per patient. A total of 42 SLN were identified
with a median of 2 SLN per patient. Two SLN were detected in 50%
(8/16) cases. The ratio of metastatic SLN was 31.0% (13/42), with a
range of zero to four positive SLN per patient. In 12.5% (2/16) of
cases only the SLN had metastases. The amount of non-sentinel
lymph nodes (NSLN) in CCD was 187, with a median of 10 (2e18)
NSLN per patient. The ratio of metastases in NSLN was 10.2% (19/
187).Fig. 1. CONSORT flow diagram of study patients.
LN, lymph node; NSLN, non-sentinel lymph node; SLN, sentinel lymph node; mSLNB, magn
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Among the patients, 56.25% (9/16) had no nodal involvement in
the central compartment (pN0). Out of the total, 43.75% (7/16) ofetic sentinel lymph node biopsy.
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Table 2
Sentinel lymph node procedure using SPIO with Sentimag-Sienna
System®.
N (%)
Magnetic tracer migration
Yes 17 (85.0%)
No 3 (15.0%)
Magnetic tracer counta
Compartment 1 800 (150e5.600)
Compartment 2 1.300 (500e5.700)
Sentinel Compartment (n¼17)
Nº areas excised
1 17 (85.0%)
2 3 (15.0%)
Lymphatic Node
Yes 16 (94.1%)
No 1 (5.9%)
Nº lymph nodes
0 1 (5.9%)
1 4 (23.5%)
2 8 (47.1%)
3 1 (5.9%)
5 2 (11.8%)
9 1 (5.9%)
Lymphatic drainage
ipsilateral 13 (65.0%)
contralateral 0 (0.0%)
bilateral 2 (12.5%)
central 2 (12.5%)
a Data as median and range.
Table 3
Lymph node assessment in successful sentinel lymph node biopsy.
Mean (SD) Median (min, max)
Lymph nodes
Nº total LN (n¼ 229) 11.5 (6.0) 12 (3e23)
Nº LN metastases (n¼ 32) 1.6 (2.5) 0 (0e9)
Sentinel Compartment
Nº SLN detected (n¼ 42) 2.6 (2.1) 2 (1e9)
Nº SLN metastases (n¼ 13) 0.8 (1.2) 0 (0e4)
Central Compartment Dissection
Nº NSLN detected (n¼ 187) 9.4 (5.4) 10 (2e18)
Nº NSLN metastases (n¼ 19) 1.0 (1.9) 0 (0e7)
LN, lymph nodes; NSLN, non-sentinel lymph nodes.
Table 4
Predictive performance of the central compartment status by sentinel lymph node
biopsy.
NSLN
þ e
SLN þ 5 (31.25%) 2 (12.50%) 7
e 0 (00.00%) 9 (56.25%) 9
5 11 16
Accuracy 87.5%
Se 100.0%
Sp 81.8%
PPV 71.4%
NPV 100.0%
SLN, sentinel lymph node; NSLN, non-sentinel lymph node; Se, sensitivity; Sp,
specificity; PPV, positive predictive value; NPV, negative predictive value.
J.A. Baena Fustegueras et al. / European Journal of Surgical Oncology xxx (xxxx) xxx4patients had positive SLN (Table 4). Among them, 28.6% (2/7) had
negative NSLN and 71.4% (5/7) had positive NSLN. No significant
differences were observed (p-value¼ 0.5, McNemar test). No false
negative cases were found; all patients with positive NSLN had
positive SLN. The performance to predict NSLN involvement by
SLNB status showed 100% sensitivity, 81.8% specificity, 71.4% PPV
and 100% NPV, with an accuracy of 87.5%.Discussion
Different strengths of recommendations are reported in the
current guidelines for the management of thyroid cancer [36e39].
Currently, the American Thyroid Association (ATA) recommends
avoiding CCD for small (T1 or T2), non-invasive, clinically negative
nodes PTC (cN0) and for most follicular cancers [2]. On the other
hand, prophylactic CCD should be considered in cN0 patients who
have advanced primary tumours (T3 or T4), clinical involvement of
lateral neck nodes (cN1b), or when the information will be used to
plan further steps in therapy. Nonetheless, the prophylacticPlease cite this article as: Baena Fustegueras JA et al., Magnetic detection o
study results, European Journal of Surgical Oncology, https://doi.org/10.1performance of central lymph node dissection is currently under
debate [3]. Defenders state that the procedure results in minimal
morbidity, reduces the postoperative thyroglobulin levels and the
risk of recurrence. Opponents to routine dissection underscore the
higher risk of postsurgical hypoparathyroidism, the increased risk
of recurrent laryngeal nerve lesions and the lack of evidence con-
cerning improved clinical outcomes. Therefore, we aim to investi-
gate the feasibility of SLNB using SPIO to discriminate patients who
would certainly benefit from central compartment dissection, the
clinical staging notwithstanding. At present this is the first study
reporting SLNB guided by a magnetic tracer in PTC.
The meta-analysis of Balasubramanian and Harrison showed
pooled detection rates of 84% and 98% for vital dyes and the
radioisotope technique, respectively [20]. The low sensitivity, close
to 65%, and the FNR over 30% of blue dyeing make the technique
inadequate for routine procedures [18]. Moreover, the adverse re-
actions and unavoidable staining of parathyroid glands increase
their drawbacks [15]. Radio-guided SLN (rSLNB) achieves better
detection rates in comparison with vital dyes, avoids lymphatic
disruption during surgery and false negative from parathyroid
glands, and allow SLN outside the central compartment to be
identified [24,40]. Recently, other methodologies such as carbon
nanoparticle suspension are being investigated as a technique for
SLNB and parathyroid gland recognition [41,42]. We achieved
satisfactory mSLNB performance with an 80% detection rate. In
addition, we observed satisfactory accuracy of mSLNB for NSLN
status based on definitive pathological assessment of LN, with 100%
sensitivity and 100% NPV, which supports the methodology as a
surgical procedure to stage PTC more effectively with clinical-
negative nodes in the central compartment. Interestingly, in our
case series there were no false negative cases of SLN according to
NSLN status whereas other studies that have attempted post-
operative pathological analysis have reported higher false negative
SLN [27]. However, the reduced sample size limits the statistical
significance of our results and further studies with extended series
of patients are needed to enhance and confirm the results.
SPIO offers an alternative procedure for SLNB in breast cancer
with notable detection rates, equal to the reference by rSLNB
[29e34]. Directly managed by surgeons, the SPIO technique using
Sentimag-Sienna System® helps to avoid radiological exposure in
addition to offering an operative solution to institutions without
nuclear medicine facilities. Managing mSLNB in thyroid cancer is
likely to demand further surgical expertise due to the limited
operative area in the central compartment making it difficult to
dissect individual SLN. Therefore, the sentinel compartment
concept may be favoured over the SLN for mSLNB procedure in PTC.
Nonetheless, we mostly retrieved 1e2 SLN per patient though onef sentinel lymph node in papillary thyroid carcinoma: TheMAGIC-PAT
016/j.ejso.2019.03.017
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negative nodes. Additionally, the tracer dose and injection method
may need to be adjusted for thyroid carcinoma due to the tumour
size and surgical area in comparison with what is established in
breast cancer.
Current ATA guidelines do not recommend CCD in PTC patients
with T1-T2 and no clinical evidence of LN metastasis. Rubello et al.
argued that the rSLNB procedure may help to improve patient
staging due to the high ratio of metastases in deferred histological
examination while negative SLN could lead to radio-metabolic
therapy [40]. Extrathyroidal extension (ETE) as well as nodal
involvement are considered prognostic risk factors in PTC [43e45].
Additionally, a 10-year follow-up of 253 patients showed a higher
risk of recurrence in accordance with T and N stages [46]. In fact,
50% (4/8) of pathological-confirmed T1/T2 patients included in the
study showed central neck node involvement. Therefore, mSLNB
improved nodal staging that could have guided surgeons to pro-
ceed with selective prophylactic CCD. On the other hand, the final
pathological examination showed 60% (12/20) of cases with a T3
tumour, all cases with minimal ETE. Among them, 7 (58.3%) cases
were pN0. ATA guidelines recommend therapeutic CCD in T3 tu-
mours. Our results, suggest that mSLNB can improve nodal staging
of patients with minimal ETE, helping surgeons to decide to dis-
continue CCD. These results are in line with guidelines, with nodal
invasion extension a better clinical factor to proceed with CCD
rather than tumour size. However, we must be aware that skip
metastases in patients with negative central neck reaches up to 20%
[36,47]. Consequently, the controversy surrounding the lymph
node dissection with regards to SLNB is still present. Further pro-
spective studies should be addressed in order to evaluate the
clinical value and prognosis of patients managed according to
mSLNB status.
In our series, CCD evidenced up to 45% (9/20) patients with
nodal involvement in the central compartment. Of these patients,
77.8% (7/9) had mSLNB, all cases with positive SLN (Table 5). Two
cases had only SLN affected. As SLNB dissection removed the whole
tumour load in the central compartment, these patients would not
have benefited from further CCD extension but would have expe-
rienced its drawbacks. Although isolated tumour cells by histo-
logical assessment denotes positive SLN, it is unlikely to find further
NSLN involvement. Using a more accurate method for LNTable 5
Node involvement and characteristics of PTC patients subjected to mSLNB.
ID Gender Age Clinical
diagnosis
cT
stage
Tumour
localization
Multifocality Tumour size
(mm)
Trac
mig
1 m 53 ultrasound T1 right no 15 yes
2 f 69 ultrasound T2 left no 40 yes
3 f 54 others T2 right yes 22 yes
4 f 50 others T1 isthmus no 15 yes
6 f 36 palpation T2 right no 21 yes
7 m 67 ultrasound T2 left yes 30 yes
8 m 69 palpation T1 right yes 15 yes
9 f 55 ultrasound T1 left no 18 no
10 f 77 ultrasound T2 left yes 25 yes
11 f 60 palpation T1 left no 10 yes
12 f 22 ultrasound T1 left no 18 yes
13 f 37 palpation T1 right no 15 no
14 f 55 ultrasound T2 isthmus yes 8 yes
15 f 60 ultrasound T1 right no 15 yes
17 f 78 palpation T2 left no 50 no
18 m 58 ultrasound T1 left no 10 yes
19 f 28 palpation T2 left no 48 yes
20 m 29 palpation T2 right no 18 yes
21 f 66 ultrasound T1 right no 10 yes
22 f 72 ultrasound T2 isthmus no 21 yes
F, female; M, male; LN, lymph node; SC, sentinel compartment; SLN, sentinel lymph nod
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improving the prediction of LN as has been proven in breast cancer
patients [48].
Besides, the feasibility of SLNB in PTC is still under discussion
due to the high rate of intraoperative false negatives [27]. Despite
the high detection rate of rSLNB, an overall intraoperative FNR of
25.4% has been reported in the meta-analysis of studies that con-
ducted SLN and lymphadenectomy in the same compartment [27].
Portinari and Carcofor suggest that considering the high FNR, rSLNB
status alone cannot justify the neck dissection procedure, rather it
can improve locoregional nodal staging and selection for post-
operative radioiodine ablation therapy [27,36]. However, authors
argue that based on lymphatic drainage rSLNB can lead to
extending dissection in a specific neck compartment (i.e., central or
lateral). Cunningham et al. reached a satisfactory 90% SLN detection
rate using blue dye but with a high FNR (34%) of intraoperative
analysis of SLN status with the frozen section, with 60% negative
NSLN after CCD pathological examination [21]. Pelizzo et al. had a
99% rSLNB detection rate and conducted lymphadenectomy only in
the same compartment of the SLN according to the frozen section
[16]. However, they found a disease persistence of 5.1%, likely due to
the selective compartment dissection or high FNR in the frozen
section analysis. Unfortunately, no data was available regarding the
status of NSLN in patients with negative SLN, and subsequently, the
false negative SLN and FNR in the final pathological analysis could
not be evaluated. Interestingly, some studies indicate the molecular
assay OSNA (one-step nucleic acid amplification) as a useful and
accurate method to detect LN metastasis in PTC [49,50]. Therefore,
intraoperative SLNB using OSNA could contribute to decreasing the
FNR formed by missed occult metastases in the intraoperative
frozen sections. Further studies should be addressed to investigate
the feasibility of mSLNB using SPIO in combination with the OSNA
assessment of SLN.
Neck dissection is known to increase morbidity, hospitalization
and costs [7]. However, rSLNB demands special facilities and also
entails adverse radiological effects on physicians and patients.
Balasubramanian et al. stated that even though morbidity attrib-
utable to CCD may be avoided, rSLNB implementation for selective
prophylactic CCD even in ideal conditions (100% detection rate,
100% sensitivity and 0% FNR) has low cost benefits [51]. In contrast,
our results suggest that mSLNB could overcome such limitationser
ration
LN
drainage
Nº
SC
SC_LN Nº
SLN
positive
SLN
Nº
NSLN
positive
NSLN
pT
stage
pN
stage
ipsilateral 1 yes 5 1 18 1 T1 N1
ipsilateral 1 yes 1 1 14 1 T2 N1
ipsilateral 1 yes 1 1 11 5 T3 N1
central 1 yes 2 0 16 0 T3 N0
ipsilateral 1 yes 2 2 17 7 T2 N1
ipsilateral 1 yes 2 0 12 0 T2 N0
ipsilateral 2 yes 2 0 10 0 T3 N0
e e e e e 5 0 T1 N0
ipsilateral 1 yes 1 0 2 0 T2 N0
ipsilateral 1 yes 9 0 6 0 T3 N0
ipsilateral 1 yes 3 3 16 2 T3 N1
e 1 yes e e 11 1 T3 N1
central 1 no e e 3 0 T1 N0
ipsilateral 1 yes 2 0 2 0 T3 N0
e e e e e 5 2 T3 N1
ipsilateral 1 yes 2 0 10 0 T3 N0
bilateral 2 yes 5 4 3 0 T2 N1
ipsilateral 1 yes 1 1 6 0 T3 N1
ipsilateral 1 yes 2 0 15 0 T3 N0
bilateral 2 yes 2 0 5 0 T3 N0
e; NSLN, non-sentinel lymph node.
f sentinel lymph node in papillary thyroid carcinoma: TheMAGIC-PAT
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implement a SLNB programme in PTC surgery for institutions
without nuclear medicine facilities.
In conclusion, we have demonstrated a satisfactory performance
of mSLNB in PTC with clinically negative nodes in the central
compartment. mSLNB improves PTC patient staging, which can
help physicians to tailor RAI treatment and follow-up. Additionally,
mSLNB helps to optimize the benefits of the CCD procedure in PTC
patients, thereby not only preventing subsequent surgical proced-
ures due to recurrence in the central compartment in T1/T2 pa-
tients but also reducing CCD morbidity in T3 with minimal
extrathyroidal extension with pathological-negative nodes. None-
theless, further prospective studies are needed to validate the
clinical value of mSLNB.
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